Investor News

Oxford Vacmedix appoints Dr Nam Park as Chief Business Officer

The appointment of Dr Nam Park as Chief Business Officer brings further expertise in venture financing and capital markets to Oxford Vacmedix Oxford, UK – 16th January 2025 Press Release – Appointment of Dr Nam Park 16-Jan-25 Oxford Vacmedix (OVM), the UK-based biopharma company focused on development of therapeutic cancer vaccines, announced today that Dr […]

Oxford Vacmedix appoints Dr Nam Park as Chief Business Officer Read More »

Innovate UK award to OVM for clinical development of OVM-200

Oxford Vacmedix receives an Investor Partnership award from Innovate UK for the clinical development of lead cancer vaccine OVM-200. Oxford, UK _ 9 January 2025 Press Release – Innovate UK Award 09-Jan-25 Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, confirmed today the grant of a prestigious Investor Partnership award from

Innovate UK award to OVM for clinical development of OVM-200 Read More »

UK charity Prostate Cancer Research invests in Oxford Vacmedix Series B

Support from leading Prostate cancer charity for the clinical development of OVM-200. Oxford, UK – 27th November 2024 Press Release – Prostate Cancer Research invests in Oxford Vacmedix Series B Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, announced today Series B investment from Proven Connect, the translational arm of the charity

UK charity Prostate Cancer Research invests in Oxford Vacmedix Series B Read More »

Oxford Vacmedix announces lead investment for Series B fund

Lead investment of $3.0 million in Oxford Vacmedix Series B from existing investors. Oxford, UK – 6th November 2024 Press Release – Oxford Vacmedix announces lead investment for Series B fund Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today the lead investment in its Series B fund of $3.0m

Oxford Vacmedix announces lead investment for Series B fund Read More »

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays.  Project with Department of Oncology, University of Oxford and Reading Scientific Services (RSSL) to develop the methodology for T-cell potency assays of vaccines. Oxford, 25th May 2022 Press Release – Innovate UK funding for development of novel T-cell potency assays Oxford Vacmedix

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays Read More »

Mr Chong-Yoon Lim of Hanmi Science appointed as a Director

Appointment brings in-depth expertise of company development and investment and enhanced contacts in Asia to Oxford Vacmedix Press Release – Appointment of Mr Choon-Yoon Lim as Director Oxford 19th October 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of cancer vaccines announced today the appointment of Mr. Chong-Yoon Lim as a

Mr Chong-Yoon Lim of Hanmi Science appointed as a Director Read More »